Introduction
Knee joint wear is common and can cause stiffness, discomfort and difficulty moving. Many people would prefer a non-surgical option before considering more invasive procedures. This article looks at how collagen injections such as ChondroFiller are shaping non-surgical knee care, with realistic expectations throughout.
The Rise of Non-Surgical, Collagen-Based Injections
An interesting development in joint care is the use of injectable collagen-based gels. Rather than simply easing pain, these are designed to be placed into the joint without surgery and to support it by adding a biological, protective layer over worn surfaces. The goal is joint preservation — slowing deterioration and supporting the tissue environment — rather than replacement or guaranteed repair.
How ChondroFiller Supports the Knee
ChondroFiller is a Class III CE-marked type I collagen hydrogel scaffold, made by Meidrix Biomedicals in Germany. It is acellular — meaning it contains no donor cells — and works by self-gelling within a few minutes of being placed at the site of cartilage wear. The scaffold then provides a physical and biological framework that recruits the patient's own progenitor cells to migrate in and begin remodelling towards cartilage tissue.
As a non-surgical procedure, the ChondroFiller injection is delivered as an ultrasound-guided outpatient injection into the knee. There is no theatre, no incision and no general anaesthetic. Once in place, the gel may settle over worn surfaces, adding a cushioning layer that helps reduce grinding. It is best understood as a supportive, joint-preserving injection — not a guaranteed repair, cure or reversal of arthritis. Benefits vary between patients.
Distinguishing the Injection from Surgical Pathways
It is worth being clear about terminology, as it affects which patients are suited to which approach. The ChondroFiller injection — described throughout this article — is a non-surgical, clinic-based procedure suited to accessible lesions and smaller joints where the scaffold can be placed precisely without the need for a theatre setting.
A separate, surgical pathway also exists at LCC: the Liquid Cartilage procedure (the Lee Liquid Cartilage Protocol). This is a keyhole (arthroscopic) surgical technique that places ChondroFiller into the joint under a dry arthroscopic field, combined with biological adjuncts such as platelet-rich fibrin, platelet-rich plasma and, where indicated, the patient's own mesenchymal stem cells from bone marrow or fat. It requires theatre, anaesthetic and a structured rehabilitation programme and is typically used for larger or load-bearing cartilage defects in the knee, hip, shoulder or ankle. These two pathways — the injection and the keyhole surgical procedure — are distinct, and clinical assessment determines which is appropriate for a given patient and defect.
What the Evidence Suggests
Published clinical experience with ChondroFiller indicates biological potential across several joints. A 2023 study of thumb-base osteoarthritis reported improvements in pain and grip strength following ChondroFiller treatment (Corain et al., 2023, Cartilage). As with any regenerative procedure, individual responses vary and benefits cannot be guaranteed. Imaging and functional assessment are used to track progress in the months following the injection.
Assessment and Patient Selection
Not everyone with knee joint wear will be suitable for a collagen injection. Careful assessment using imaging and clinical examination is required to identify the nature, size and location of the cartilage lesion, as well as the overall condition of the joint. Patients with early-to-moderate focal wear in a well-aligned, stable knee tend to be the most appropriate candidates. Those with advanced, widespread arthritis or significant structural problems may require a different approach — which is precisely why an expert assessment matters before any regenerative treatment is considered.
Looking Ahead: Non-Surgical Joint Care
Joint care is moving steadily towards minimally invasive, joint-preserving options that follow a support-not-replace philosophy. Collagen injections such as ChondroFiller are part of this shift, sitting within a broader spectrum of non-surgical tools that also includes hyaluronic acid, platelet-rich plasma and physical rehabilitation. The aim in each case is to slow deterioration and improve the joint environment for as long as possible, delaying or — in some patients — avoiding the need for joint replacement surgery.
Conclusion
Collagen injections like ChondroFiller offer a non-surgical way to support a worn knee and ease symptoms for appropriate patients. The approach is biologically active rather than simply palliative, but it is not a cure and responses vary. For patients with larger or more demanding defects, a surgical approach such as the Liquid Cartilage keyhole procedure may be more appropriate. A specialist assessment will clarify which pathway suits you best. The London Cartilage Clinic offers assessment for both non-surgical and surgical cartilage options if you would like personalised guidance.
References
Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.
Frequently Asked Questions
- ChondroFiller is a CE-marked type I collagen hydrogel scaffold that is delivered as an ultrasound-guided outpatient injection into the knee. There is no surgery, no incision and no general anaesthetic. Once injected, it self-gels over a few minutes and may settle over worn cartilage surfaces, providing a supportive, cushioning layer.
- The ChondroFiller injection is a non-surgical, clinic-based procedure. The Liquid Cartilage procedure (the Lee Liquid Cartilage Protocol) is a keyhole surgical technique performed in theatre under anaesthetic, which places ChondroFiller alongside biological adjuncts such as platelet-rich fibrin and, where indicated, mesenchymal stem cells. The surgical route is typically used for larger or load-bearing cartilage defects. Clinical assessment determines which is appropriate.
- No. ChondroFiller is a joint-preserving, biologically active scaffold. It may help cushion the joint and support the tissue environment, but it does not cure or reverse arthritis. Benefits vary between patients, and cautious, evidence-based expectations are important before any regenerative treatment.
- Patients with early-to-moderate focal cartilage wear in a well-aligned, stable knee tend to be the most appropriate candidates. Those with advanced or widespread arthritis, significant malalignment, or larger structural defects may require a surgical approach such as the Liquid Cartilage procedure instead. A clinical assessment including imaging is needed to determine suitability.
- Recovery from a non-surgical injection is simpler than from surgery. There is typically a period of modified activity to allow the scaffold to settle. Imaging and functional follow-up are used to assess how the joint responds over subsequent months. As with any regenerative treatment, improvement is gradual and individual responses vary.
Where to go from here
A few next steps tailored to what you have just read.
Legal & Medical Disclaimer
This article is written by an independent contributor and reflects their own views and experience, not necessarily those of London Cartilage Clinic. It is provided for general information and education only and does not constitute medical advice, diagnosis, or treatment.
Always seek personalised advice from a qualified healthcare professional before making decisions about your health. London Cartilage Clinic accepts no responsibility for errors, omissions, third-party content, or any loss, damage, or injury arising from reliance on this material.
If you believe this article contains inaccurate or infringing content, please contact us at [email protected].
